|
1
|
Pukazhendhi G and Glück S: Circulating
tumor cells in breast cancer. J Carcinog. 13:82014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Alix-Panabieres C and Pantel K: Challenges
in circulating tumor cell research. Nat Rev Cancer. 14:623–631.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pantel K, Alix-Panabières C and Riethdorf
S: Cancer micrometastases. Nat Rev Clin Oncol. 6:339–351. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pantel K and Alix-Panabières C: Real-time
liquid biopsy in cancer patients: Fact or fiction? Cancer Res.
73:6384–6388. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ilie M, Hofman V, Long E, Bordone O, Selva
E, Washetine K, Marquette CH and Hofman P: Current challenges for
detection of circulating tumor cells and cell-free circulating
nucleic acids, and their characterization in non-small cell lung
carcinoma patients. What is the best blood substrate for
personalized medicine? Ann Transl Med. 2:1072014.PubMed/NCBI
|
|
6
|
Alix-Panabieres C and Pantel K: The
circulating Tumor Cells: liquid biopsy of cancer. Klin Lab Diagn.
4:60–64. 2014.(In Russian).
|
|
7
|
Allard WJ, Matera J, Miller MC, Repollet
M, Connelly MC, Rao C, Tibbe AG, Uhr JW and Terstappen LW: Tumor
cells circulate in the peripheral blood of all major carcinomas but
not in healthy subjects or patients with nonmalignant diseases.
Clin Cancer Res. 10:6897–6904. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sestier C, Lacava ZGM, Lacava LM, Da Silva
MF and Azevedo RB: In vitro toxicity of magnetic fluids evaluated
for macrophage cell lines. J Magn Magn Mater. 252:403–405. 2002.
View Article : Google Scholar
|
|
9
|
Tiwari A, Punshon G, Kidane A, Hamilton G
and Seifalian AM: Magnetic beads (Dynabead) toxicity to endothelial
cells at high bead concentration: Implication for tissue
engineering of vascular prosthesis. Cell Biol Toxicol. 19:265–272.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rao CG, Chianese D, Doyle GV, Miller MC,
Russell T, Sanders RA Jr and Terstappen LW: Expression of
epithelial cell adhesion molecule in carcinoma cells present in
blood and primary and metastatic tumors. Int J Oncol. 27:49–57.
2005.PubMed/NCBI
|
|
11
|
Sieuwerts AM, Kraan J, Bolt J, van der
Spoel P, Elstrodt F, Schutte M, Martens JW, Gratama JW, Sleijfer S
and Foekens JA: Anti-epithelial cell adhesion molecule antibodies
and the detection of circulating normal-like breast tumor cells. J
Natl Cancer Inst. 101:61–66. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Johnson RH, Chien FL and Bleyer A:
Incidence of breast cancer with distant involvement among women in
the United States, 1976 to 2009. JAMA. 309:800–805. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vogel CL, Cobleigh MA, Tripathy D, Gutheil
JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF,
Burchmore M, et al: Efficacy and safety of trastuzumab as a single
agent in first-line treatment of HER2-overexpressing metastatic
breast cancer. J Clin Oncol. 20:719–726. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Spector NL, Xia W, Burris H III, Hurwitz
H, Dees EC, Dowlati A, O'Neil B, Overmoyer B, Marcom PK, Blackwell
KL, et al: Study of the biologic effects of lapatinib, a reversible
inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and
survival pathways in patients with advanced malignancies. J Clin
Oncol. 23:2502–2512. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fernandez SV, Bingham C, Fittipaldi P,
Austin L, Palazzo J, Palmer G, Alpaugh K and Cristofanilli M: TP53
mutations detected in circulating tumor cells present in the blood
of metastatic triple negative breast cancer patients. Breast Cancer
Res. 16:4452014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pestrin M, Salvianti F, Galardi F, De Luca
F, Turner N, Malorni L, Pazzagli M, Di Leo A and Pinzani P:
Heterogeneity of PIK3CA mutational status at the single cell level
in circulating tumor cells from metastatic breast cancer patients.
Mol Oncol. 9:749–757. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
American Joint Committee on Cancer: AJCC
Cancer Staging Manual. 7th. Springer; New York, NY: 2010
|
|
18
|
Kim EH, Lee JK, Kim BC, Rhim SH, Kim JW,
Kim KH, Jung SM, Park PS, Park HC, Lee J and Jeon BH: Enrichment of
cancer cells from whole blood using a microfabricated porous
filter. Anal Biochem. 440:114–116. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Columns FA, van Dalum G, Beck M and
Terstappen LW: Filter characteristics influencing circulating tumor
cell enrichment from whole blood. PLoS One. 8:e617702013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kallioniemi OP, Kallioniemi A, Kurisu W,
Thor A, Chen LC, Smith HS, Waldman FM, Pinkel D and Gray JW: ERBB2
amplification in breast cancer analyzed by fluorescence in situ
hybridization. Proc Natl Acad Sci USA. 89:5321–5325. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gretarsdottir S, Thorlacius S,
Valgardsdottir R, Gudlaugsdottir S, Sigurdsson S, Steinarsdottir M,
Jonasson JG, Anamthawat-Jonsson K and Eyfjörd JE: BRCA2 and p53
mutations in primary breast cancer in relation to genetic
instability. Cancer Res. 58:859–862. 1998.PubMed/NCBI
|
|
22
|
Janku F, Wheler JJ, Westin SN, Moulder SL,
Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna
I, et al: PI3K/AKT/mTOR inhibitors in patients with breast and
gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol.
30:777–782. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Arnold JM, Choong DY and Thompson ER:
kConFab, Waddell N, Lindeman GJ, Visvader JE, Campbell IG and
Chenevix-Trench G: Frequent somatic mutations of GATA3 in
non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2-
or sporadic breast tumors. Breast Cancer Res Treat. 119:491–496.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hu T and Li C: Convergence between
Wnt-β-catenin and EGFR signaling in cancer. Mol Cancer. 9:2362010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Augello MA, Burd CJ, Birbe R, McNair C,
Ertel A, Magee MS, Frigo DE, Wilder-Romans K, Shilkrut M, Han S, et
al: Convergence of oncogenic and hormone receptor pathways promotes
metastatic phenotypes. J Clin Invest. 123:493–508. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Stephens PJ, Tarpey PS, Davies H, Van Loo
P, Greenman C, Wedge DC, Nik-Zainal S, Martin S, Varela I, Bignell
GR, et al: The landscape of cancer genes and mutational processes
in breast cancer. Nature. 486:400–404. 2012.PubMed/NCBI
|
